

University of Groningen

Innate immune checkpoint inhibitors for treatment of Diffuse Large B-cell Lymphoma

Bouwstra, Renée

DOI:
[10.33612/diss.234614293](https://doi.org/10.33612/diss.234614293)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Bouwstra, R. (2022). *Innate immune checkpoint inhibitors for treatment of Diffuse Large B-cell Lymphoma*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.234614293>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Innate Immune Checkpoint Inhibitors for Treatment of Diffuse Large B-cell Lymphoma

Renée Bouwstra

Cover design and lay-out: Publiss | www.publiss.nl

Print: Ridderprint | www.ridderprint.nl

© Copyright 2022: Renate Bouwstra, Groningen , The Netherlands

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, by photocopying, recording, or otherwise, without the prior written permission of the author.



rijksuniversiteit
groningen

Innate immune checkpoint inhibitors for treatment of Diffuse Large B-cell Lymphoma

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op
woensdag 21 september 2022 om 12.45 uur

door

Renate Elisabeth Bouwstra

geboren op 27 mei 1994
te Utrecht

Promotores

Prof. dr. E. Bremer

Prof. dr. G.A. Huls

Copromotor

Dr. T. van Meerten

Beoordelingscommissie

Prof. dr. J.D. Laman

Prof. dr. T. Mutis

Table of content

| | | |
|-------------------|--|-----|
| CHAPTER 1 | General introduction and scope of the thesis | 7 |
| CHAPTER 2 | Review: CD47-SIRP α blocking-based immunotherapy; current and prospective therapeutic strategies | 21 |
| CHAPTER 3 | CD20 directed CD47 blockade by RTX-SIRP α and SIRP α -RTX, a functional comparison | 53 |
| CHAPTER 4 | CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL | 77 |
| CHAPTER 5 | CD300a is a novel immune checkpoint regulating innate anticancer immune responses | 105 |
| CHAPTER 6A | Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis | 147 |
| CHAPTER 6B | Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis? | 169 |
| CHAPTER 7 | Summary, discussion and perspectives | 177 |
| CHAPTER 8 | Nederlandse samenvatting en dankwoord | 201 |

